Brief: Beyondspring Enrolls First Patient In Mid-stage Lung Cancer Study
01/03/2023 13:57
March 1 (Reuters) - Beyondspring Inc BYSI.O :
* BEYONDSPRING ENROLLS FIRST PATIENT IN PHASE 2 STUDY WITH
PLINABULIN, KEYTRUDA AND DOCETAXEL IN PATIENTS WITH METASTATIC
NON-SMALL CELL LUNG CANCER WHO PROGRESSED AFTER IMMUNOTHERAPY
Source text for Eikon: ID:nGNXb0tVWn
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value